Evidence map›Paper›PMID 37444432›Full record

ArticleCancers2023

Oncological and Peri-Operative Outcomes of Percutaneous Cryoablation of Renal Cell Carcinoma for Patients with Hereditary RCC Diseases-An Analysis of European Multi-Centre Prospective EuRECA Registry.

Filzah Hanis Osman, Vinson Wai-Shun Chan, David J Breen, Alexander King, Tommy Kjærgaard Nielsen, Julien Garnon, Des Alcorn, Brunolf Lagerveld, Ole Graumann, Francis Xavier Keeley and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 4 countries.

Filzah Hanis OsmanSchool of Medicine, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK.
Vinson Wai-Shun ChanLeeds Institute of Medical Research, University of Leeds, Leeds LS2 9JT, UK.ORCID 0000-0002-6108-9315
David J BreenDepartment of Radiology, Southampton University Hospitals, Southampton SO16 6YD, UK.
Alexander KingDepartment of Radiology, Southampton University Hospitals, Southampton SO16 6YD, UK.
Tommy Kjærgaard NielsenDepartment of Urology, Aarhus University Hospital, 8200 Aarhus, Denmark.
Julien GarnonDepartment of Interventional Radiology, Nouvel Hôpital Civil, 1 Place de l'Hôpital, 67000 Strasbourg, France.
Des AlcornDepartment of Interventional Radiology, Gartnavel General Hospital, Glasgow G12 0YN, UK.
Brunolf LagerveldDepartment of Urology, OLVG, Amsterdam 1091 AC, The Netherlands.ORCID 0000-0003-3841-6805
Ole GraumannDepartment of Radiology, Odense University Hospital, 5000 Odense, Denmark.
Francis Xavier KeeleyBristol Urological Institute, North Bristol NHS Trust, Bristol BS10 5NB, UK.
Miles WalkdenDepartment of Imaging, University College London Hospitals NHS Foundation Trust, London WC1N 3BG, UK.
Éric de KervilerRadiology Department, Saint-Louis Hospital, AP-HP, 1 Avenue Claude-Vellefaux, 75475 Paris, CEDEX 10, France.
Tze Min WahLeeds Institute of Medical Research, University of Leeds, Leeds LS2 9JT, UK.ORCID 0000-0001-5670-5454
University of Leeds · GBAarhus University Hospital · DKAssistance Publique – Hôpitaux de Paris · FRGartnavel General Hospital · GBHôpital Civil, Strasbourg · FRNorth Bristol NHS Trust · GBOdense University Hospital · DKOLVG · NLUniversity College London Hospitals NHS Foundation Trust · GB

Funding

Boston Scientific (United States)
6 · The paper itself

Abstract

This study aims to evaluate the safety, efficacy, and renal function preservation of percutaneous cryoablation (PCA) for small renal masses (SRMs) in inherited RCC syndromes. Patients with inherited T1N0M0 RCCs (<7 cm) undergoing PCA from 2015 to 2021 were identified from the European Registry for Renal Cryoablation (EuRECA). The primary outcome was local recurrence-free survival (LRFS). The secondary outcomes included technical success, peri-operative outcomes, and other oncological outcomes estimated using the Kaplan-Meier method. Simple proportions, chi-squared tests, and

Indexed as

hereditary RCCimage-guided cryoablationinherited RCCpercutaneous cryoablationrenal cell carcinomasmall renal massesVon-Hipple Lindau disease

Identifiers

PMID37444432
PMCPMC10340367
OpenAlexW4382061889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.